

FOI 3580

18th February 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

1. How many patients have been diagnosed with Acute Myeloid Leukaemia (AML) at your Trust in the last 12 months

Response:

5 patients newly diagnosed

- a. **Of these patients how many are refractory/relapsed (R/R)?**
- b. **How many of the R/R patients were FLT3 positive?**

Response:

This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

2. How many patients have been treated for AML in the latest 12 months with the following treatments

- **Venetoclax with azacitidine**
- **Midostaurin**
- **Quizartinib**
- **Gemtuzumab**
- **Ivosidenib with azacitidine**
- **Liposomal cytarabine–daunorubicin**

- **Oral azacitidine**
- **Gilteritinib**
- **Palliative care**
- **Enrolled in a clinical trial**

Response:

The information is not recorded centrally on our pharmacy system. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

3. How many relapsed/refractory patients have been treated for AML in the last 12 months with the following treatments (This question relates to treatments administered to relapsed/refractory AML patients in clinical practice, regardless of licence status or funding route (including any off-label use).

- **Venetoclax with azacitidine**
- **Midostaurin**
- **Quizartinib**
- **Gemtuzumab**
- **Ivosidenib with azacitidine**
- **Liposomal cytarabine–daunorubicin**
- **Oral azacitidine**
- **Gilteritinib**
- **Palliative care**
- **Enrolled in a clinical trial**

Response:

The information is not recorded centrally on our pharmacy system. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

4. Of your AML patients how many were tested as below in the last 12 months

- **Received an FLT3 mutation test when they were diagnosed**
- **Received an FLT3 mutation test when their disease relapsed**
- **Received an FLT3 mutation test when their disease became refractory**

Response:

This information is not recorded centrally nor held in an easily accessible format. The Trust does not routinely review or extract information from individual patient records for the purposes of responding to Freedom of Information (FOI) requests. Accessing personal clinical records solely to answer an FOI request would involve processing personal data in a way that is not required for Trust functions and would not be lawful under data protection legislation.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient records just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Email: foi.team@southerntrust.hscni.net